论文部分内容阅读
由于各种化疗药物进入临床,暂且不说延长生存期,仅就小细胞肺癌(SCLC)病例来说确实有效(complete response,CR)或部分有效(partial response,PR)。现在与5年或10年前不同,SCLC 导致的上腔静脉阻塞综合征等病例的治疗,首先是化学疗法而不是放射疗法。将小细胞癌外的肺癌,总称为NSCLC(non-small cell lung carcinoma,非小细胞肺癌),由于顺氯氨铂(cis—platin)的导入,确实改变了NSCLC 病例的治疗。现将在
Since various chemotherapeutic agents enter the clinic, for the time being, they do not say that prolonging the survival period is only effective (complete response, CR) or partial response (PR) in cases of small cell lung cancer (SCLC). Now, unlike 5 or 10 years ago, treatment of SCVC-causing cases of superior vena cava obstruction syndrome was first chemotherapy rather than radiation therapy. The lung cancer other than small cell carcinoma, collectively referred to as NSCLC (non-small cell lung carcinoma), does change the treatment of NSCLC cases due to the introduction of cisplatin. Now will